These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 19497734)
1. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth. Grange JM; Krone B; Stanford JL Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734 [TBL] [Abstract][Full Text] [Related]
2. Vaccine therapy for melanoma: current status and future directions. Terando AM; Faries MB; Morton DL Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038 [TBL] [Abstract][Full Text] [Related]
3. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Hsueh EC; Morton DL Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158 [TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches]. Enk AH; Becker JC; Schuler G J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565 [TBL] [Abstract][Full Text] [Related]
5. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Sondak VK; Sosman JA Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of melanoma. Hersey P Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S2-8. PubMed ID: 20482529 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165 [TBL] [Abstract][Full Text] [Related]
8. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of melanoma: the good news, the bad ones and what to do next. Marincola FM; Ferrone S Semin Cancer Biol; 2003 Dec; 13(6):387-9. PubMed ID: 15001156 [No Abstract] [Full Text] [Related]
10. Melanoma vaccines: achievements and perspectives. Brichard VG; Gérard C Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881 [TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy for melanoma: how can tolerance be overcome?]. Robert C Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031 [No Abstract] [Full Text] [Related]
12. Melanoma vaccines: early progress and future promises. Zarour HM; Kirkwood JM Semin Cutan Med Surg; 2003 Mar; 22(1):68-75. PubMed ID: 12773015 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of immunotherapy in the treatment of melanoma. Faries MB Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223 [TBL] [Abstract][Full Text] [Related]
14. [Are immunological treatments beneficial for malignant melanoma of the skin?]. Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Sondak VK; Sabel MS; Mulé JJ Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055 [TBL] [Abstract][Full Text] [Related]
16. Special report: vaccines for the treatment of malignant melanoma. Tecnologica MAP Suppl; 2001 Apr; ():19-20. PubMed ID: 11718143 [TBL] [Abstract][Full Text] [Related]
17. Self-recognition and tumor response to immunotherapy. Ernstoff MS J Clin Oncol; 2005 Sep; 23(25):5875-7. PubMed ID: 16087939 [No Abstract] [Full Text] [Related]